When was Wobble Genomics founded?

Wobble Genomics was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Wobble Genomics located?

Wobble Genomics is headquartered in Edinburgh, United Kingdom.

Which legal entities is Wobble Genomics associated with?

Wobble Genomics is associated with Wobble Genomics Limited.

How many employees does Wobble Genomics have?

As of Aug 31, 2026, the latest employee count at Wobble Genomics is 19.

Is Wobble Genomics a funded company?

Wobble Genomics is a funded company, having raised a total of $12.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 02, 2021.

When was the latest funding round of Wobble Genomics?

Wobble Genomics' latest funding was a $***** Series A round on Dec 22, 2023, with participation from 5 investors. Its primary sector is Genomics. In United Kingdom, the Genomics sector has seen $90.4M in funding in 2026 to date.

Where does Wobble Genomics rank among its competitors?

Wobble Genomics ranks 6th amongst 96 active competitors, of which 30 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Wobble Genomics?

Wobble Genomics' top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Wobble Genomics - 2026 Company Profile, Team, Funding, Competitors & Financials

Wobble Genomics is a series A company based in Edinburgh (United Kingdom), founded in 2020 by Richard Kuo. It operates as a Provider of a platform for discovery of nucleic acid biomarkers. Wobble Genomics has raised $12.5M in funding from investors like Mercia, BGFG and Eos Advisory. The company has 96 active competitors, including 30 funded and 17 that have exited. Its top competitors include companies like Seer, Tango Therapeutics and Maze Therapeutics.

Company Details

Provider of a platform for discovery of nucleic acid biomarkers. The company has cDNA normalization technology Level-Up that allows non-targeted sequencing efficiency for biomarker discovery. Also, provides TAMA RNA sequencing bioinformatics software for the detection of genes.

Key Metrics

Founded Year

2020

Location

Edinburgh, United Kingdom

Stage

Series A

Total Funding

$12.5M in 2 rounds

Latest Funding Round

Series A, Dec 22, 2023, $*****

Investors

Mercia & 36 more

Ranked

6^th among 96 active competitors

Employee Count

19 as on Aug 31, 2026

Investment & Acquisitions

Log My Care

Similar Companies

Seer & 123 more

View Wobble Genomics' full profile

Wobble Genomics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Wobble Genomics Limited CIN: SC694432 , United Kingdom, Active	Apr 05, 2021	-	21 (As on Jun 30, 2025)

Wobble Genomics has raised a total funding of $12.5M over 2 rounds. Its first funding round was on Sep 02, 2021. Its latest funding round was a Series A round on Dec 22, 2023 for $*****. 5 investors participated in its latest round. Wobble Genomics has 10 institutional investors and 27 angel investors.

Here is the list of recent funding rounds of Wobble Genomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 22, 2023	2338577	Series A	7709539	4620999	7996862	2882323
Sep 02, 2021	5761712	Seed	6341050	6481726	Eos Advisory	Old College Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Wobble Genomics's funding rounds and investors

The founders of Wobble Genomics is Richard Kuo.

Here are the details of Wobble Genomics' key team members:

Richard Kuo: Founder of Wobble Genomics.
Contact Info: 1 email address

View details of Wobble Genomics's Founder profiles and Board Members

Wobble Genomics' employee count trend

Wobble Genomics has 19 employees as of Aug 26. Here is Wobble Genomics's employee count trend over the years:

Employee count trend for Wobble Genomics

Uncover Wobble Genomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Wobble Genomics include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of Wobble Genomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Matrix Capital Management, Frazier Life Sciences ... & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	64/100
6th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	IQ Capital, Old College Capital & 35 others	62/100
7th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	Guangzhou Yuexiu Industrial Investment Fund Management, CICC ... & 12 others	56/100
8th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	56/100
9th	Proteomics International 2001, Perth (Australia), Public	Medical technology company at the forefront of predictive diagnostics and bio-analytical services	-	MTPConnect, NorthStar Impact	55/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100